Blog
Drug Target Encyclopedia Series (27) —KLRK1
Release Time：
2026-01-06 11:12
KLRK1, better known as NKG2D, is an activating immunoreceptor expressed on NK cells, CD8⁺ T cells, γδ T cells, and some NKT cells.
It functions as a stress-surveillance receptor, recognizing ligands induced by cellular transformation, infection, or DNA damage.
In immuno-oncology and immune modulation, KLRK1 represents a core axis of innate–adaptive immune activation and a high-value target for restoring anti-tumor cytotoxicity.
Where KLRK1 matters biologically
NKG2D binds to stress-induced ligands such as MICA, MICB, and ULBP family proteins, which are frequently upregulated in:
• Solid tumors (lung, colorectal, ovarian, melanoma, HCC)
• Hematological malignancies
• Virus-infected or genomically unstable cells
Loss, shedding, or downregulation of NKG2D ligands is a key immune-evasion mechanism, strongly associated with tumor progression and poor prognosis.
Disease & drug development value
From a drug-discovery perspective, KLRK1 sits at the intersection of:
• Innate immune activation
• Tumor immune surveillance
• Resistance to checkpoint blockade
• NK- and T-cell–based cell therapies
Enhancing or restoring NKG2D signaling can directly boost cytotoxic lymphocyte killing, making it a strategic target beyond classical checkpoints.
Emerging therapeutic strategies targeting KLRK1
🔹 NKG2D-based CAR platforms
NKG2D CAR-T and CAR-NK cells exploit ligand overexpression across multiple tumor types, enabling broad-spectrum tumor recognition independent of HLA.
🔹 Bispecific & multispecific antibodies
Antibodies linking NKG2D ligands to CD3 or NK receptors aim to redirect immune effector cells toward stressed tumor cells.
🔹 Ligand stabilization & shedding inhibition
Blocking MICA/MICB shedding restores surface ligand density, re-sensitizing tumors to NKG2D-mediated killing.
🔹 mRNA & transient expression systems
mRNA tools are increasingly used to:
• Express NKG2D receptors or ligands transiently
• Engineer NK and T cells without permanent genomic modification
• Rapidly validate CAR and bispecific designs
• Model stress-ligand dynamics in tumor cells
Key challenges
• Tumor-mediated NKG2D ligand shedding
• Chronic stimulation leading to receptor downregulation
• On-target activity in inflammatory settings
• Translating potent cytotoxicity into durable clinical responses
Current R&D focus areas
• Next-gen NKG2D CAR-NK therapies
• Combination with PD-1 / PD-L1 blockade
• Targeting ligand biology as a biomarker strategy
• mRNA-driven immune cell engineering
• Overcoming tumor-induced NKG2D desensitization
Need KLRK1 tools for your research?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898